An Evolving Treatment Paradigm: Innovative Approaches and Critical Insights in the Management of Newly Diagnosed Multiple Myeloma

This activity was originally presented at the 2025 HOPA Annual Conference in Portland, Oregon.

Program Description

Early diagnosis and effective treatment are crucial for improving outcomes for patients with multiple myeloma. Combination therapies such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies have become standard of care, but challenges such as treatment-related adverse events, drug resistance, and relapse persist. While quadruplet regimens including these therapies are emerging as frontline treatment options, the most effective selection and sequencing strategies remain unclear, and treatment selection and optimization have become increasingly complex. Oncology pharmacists are well-positioned to address these challenges, and staying updated on the latest developments in multiple myeloma treatment is crucial. This presentation features expert insight on emerging data, considerations for induction therapy selection, and supportive care and adverse event management strategies that will help oncology pharmacists manage drug therapy for patients newly diagnosed with multiple myeloma. The included patient case examples will provide participants with the opportunity to apply evidence-based recommendations and address practical challenges regarding treatment selection and adverse event management.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 17, 2025
Expiration date: April 17, 2026

Time to complete activity: 1.0 hours

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the latest clinical evidence on quadruplet induction therapy in multiple myeloma, focusing on the risks and benefits in comparison to triplet and doublet induction strategies
• Determine patients’ eligibility for quadruplet vs triplet induction therapy in multiple myeloma, incorporating considerations of transplant eligibility
• Apply pharmacist-led strategies to enhance safety and efficacy of induction therapy for newly diagnosed multiple myeloma, prioritizing proactive toxicity management and personalized supportive care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-25-110-H01-P. The activity is available for CE credit through April 17, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

James Davis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Janssen Biotech

Speakers Bureau: Janssen Biotech

Rahul Banerjee, MD, FACP, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: AbbVie, Bristol Myers Squibb, Johnson & Johnson, Novartis, Prothena, Sanofi

Consultant: Adaptive Biotech, Bristol Myers Squibb, Caribou Biosciences, Genentech/Roche, GSK, Karyopharm, Legend Biotech, Johnson & Johnson, Pfizer, Sanofi Pasteur, SparkCures

Brooke Peters, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Amgen, Genentech, Janssen

Speakers Bureau: Amgen, Janssen, Pfizer

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms